If you are dealing with alcohol cravings, binge drinking, or difficulty controlling your alcohol intake, you are not alone. Alcohol use disorder (AUD) affects millions of people, and the available treatments, while helpful, leave many patients still struggling.
Now, emerging research on GLP-1 alcohol cravings suggests that GLP-1/GIP medications (the same medications used for medical weight loss treatment and type 2 diabetes) may offer a new tool in the fight against alcohol addiction. The science is early but promising, and it is generating enormous interest in the addiction medicine community.
Why Would a Weight Loss Medication Help with Alcohol?
It comes down to the brain’s reward system. The same neural circuits that drive food cravings also drive alcohol cravings. Both food and alcohol activate the mesolimbic dopamine pathway (the brain’s “reward center”), releasing dopamine and creating feelings of pleasure and satisfaction.
GLP-1 receptors are present throughout this reward system. When GLP-1/GIP medications activate these receptors, they modulate the dopamine response, reducing the intensity of the “reward” you get from both food and alcohol. In other words, these medications may make alcohol less rewarding, less craved, and easier to resist.
What Does the Research Show About GLP-1 and Alcohol?
The evidence is building rapidly, though most of it is still early.
The first clinical trial of semaglutide for alcohol use disorder
A phase 2 randomized controlled trial published in JAMA Psychiatry in 2025 found that semaglutide significantly reduced alcohol cravings, drinks per drinking day, and heavy drinking days compared to placebo, with medium-to-large effect sizes. This was the first rigorous clinical trial to test a GLP-1 medication specifically for alcohol use disorder. It was small (48 adults over nine weeks) and used low starting doses, so larger studies are needed to confirm the results.
A nationwide study of nearly 228,000 people
A large Swedish nationwide study, led by researchers in Finland and published in JAMA Psychiatry in 2024, followed nearly 228,000 people with alcohol use disorder. Semaglutide use was associated with a 36% lower risk of hospitalization for alcohol use disorder compared with periods when people were not taking a GLP-1 medication. Liraglutide, an older GLP-1 medication, was linked to a 28% lower risk. In the same study, standard AUD medications showed only a small reduction in hospitalizations. Because this was an observational study, it shows a link rather than proof of cause, but it is one of the strongest signals so far.
What about tirzepatide (GLP-1/GIP)?
Tirzepatide acts on both GLP-1 and GIP receptors. A 2024 study of 153 adults with obesity found that people taking semaglutide or tirzepatide reported drinking less, with fewer binge drinking episodes, than before they started the medication and compared with people not taking either drug. Animal research has also shown tirzepatide reduced alcohol intake and relapse-like drinking. A phase 2 clinical trial of tirzepatide for alcohol use disorder, funded by the National Institute on Alcohol Abuse and Alcoholism, is now underway.
Patients who cut back without trying
Multiple case reports and case series have described patients who spontaneously reduced or stopped drinking after starting GLP-1/GIP medications for weight loss or diabetes, without any intention of addressing their alcohol use. In one case series of six patients, everyone who started semaglutide for weight loss showed a significant drop in alcohol use disorder symptoms.
How Might GLP-1/GIP Medications Reduce Alcohol Use?
Reduced reward response. By modulating dopamine signaling in the brain’s reward center, GLP-1/GIP medications may make alcohol less pleasurable and less reinforcing, reducing the drive to drink.
Reduced craving intensity. Just as these medications quiet food noise, they may quiet “alcohol noise”: the persistent thoughts about drinking that make it so hard to abstain.
Improved impulse control. GLP-1 receptors in the prefrontal cortex (the brain’s decision-making center) may help improve self-control and reduce impulsive drinking, especially in triggering situations.
Mood stabilization. By reducing inflammation and improving metabolic health, GLP-1/GIP medications may help stabilize mood, reducing the anxiety, depression, and stress that often trigger drinking. If you have noticed mood changes on treatment, our guide to GLP-1 medications and low mood explains what may be going on.
Reduced cross-addiction. Many people with alcohol use disorder also struggle with food addiction or binge eating. GLP-1/GIP medications may address both simultaneously by modulating the shared reward pathways.
What Should You Know Before Trying a GLP-1 for Alcohol Cravings?
GLP-1/GIP medications are NOT yet FDA-approved for alcohol use disorder. The research is promising but still in early stages. Larger, definitive clinical trials are underway.
They should not replace established AUD treatments. These include behavioral therapy, support groups (AA, SMART Recovery), and FDA-approved medications (naltrexone, acamprosate, disulfiram).
Alcohol can make side effects worse. Alcohol use can worsen the gastrointestinal side effects of GLP-1/GIP medications (nausea, vomiting) and can stress the liver. If you are drinking heavily, talk to your provider about safe alcohol reduction strategies before starting these medications.
Never stop heavy drinking suddenly on your own. If you have severe alcohol dependence, stopping drinking abruptly can be medically dangerous (risk of seizures, delirium tremens). Always seek medical supervision for alcohol detoxification.
Can You Drink Alcohol on a GLP-1 or Tirzepatide?
It’s one of the first questions people ask when they start treatment. The short answer: alcohol isn’t strictly off-limits on semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro, Zepbound), and there’s no direct drug interaction. But that doesn’t mean drinking is risk-free, and most providers suggest keeping it light or skipping it, especially in the first few weeks.
Here’s why it matters:
Your stomach may not handle it well. GLP-1/GIP medications slow digestion, and alcohol can make nausea, bloating, vomiting, and diarrhea worse. Many people find these side effects hit hardest when they’ve just started or moved up a dose.
Dehydration adds up quickly. Alcohol makes you lose fluids. If you’re also dealing with vomiting or diarrhea from your medication, you can get dehydrated faster than you expect, which puts extra strain on your kidneys.
Pancreatitis is a real concern. Pancreatitis has been reported in some people taking these medications, and heavy drinking is one of its biggest risk factors. Severe pain in your upper abdomen that spreads to your back, with or without vomiting, needs medical attention right away.
Low blood sugar is a risk for some people. If you also take insulin or a sulfonylurea for type 2 diabetes, alcohol can push your blood sugar too low. Never drink on an empty stomach, and ask your provider whether your diabetes medications need adjusting.
It can work against your weight goals. Alcohol carries a lot of calories with little nutrition, and it tends to lower your guard around food. When you’re eating less overall, those calories take up a bigger share of your day.
If you do choose to drink, keep it to small amounts, have it with food, drink water alongside it, and pay attention to how your body reacts. Some people notice they simply want less, or that one drink is plenty. And if you find it hard to keep your drinking in check, that’s worth bringing up with your provider. It may change which treatment plan makes the most sense for you.
Should You Ask Your Provider About a GLP-1 for Alcohol Cravings?
The connection between GLP-1/GIP medications and reduced alcohol use is one of the most exciting developments in addiction medicine in years. While these medications are not yet approved for AUD, the evidence suggests GLP-1 alcohol cravings research may point to a real benefit: fewer cravings, lower consumption, and easier control over drinking, through the same brain pathways these medications use to control appetite.
If you are struggling with alcohol and are also dealing with weight or metabolic issues, talk to your provider about whether a GLP-1/GIP medication might offer dual benefits. At Everest eClinic, our board-certified nurse practitioner can review your health history, your goals, and any concerns about drinking during a private telehealth visit. Pairing medication with nutrition counseling can also help you build habits that last
Book a consultation or contact us to get started.
Frequently Asked Questions
For broader questions about our services and approach, visit our FAQ page.
Contact Everest eClinic to speak with a provider about your options.
Sincerely,
Geeta Sharma,
DNP Endocrinology Nurse Practitioner
Everest Diabetes & Weight Loss
Connecticut: 203-689-0558 Office Phone or Text
Texas: Call: 512-541-2126
Sources
- Hendershot CS, Bremmer MP, Paladino MB, et al. Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2025;82(4):395-405. https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2829811
- Lähteenvuo M, et al. Repurposing Semaglutide and Liraglutide for Alcohol Use Disorder. JAMA Psychiatry. 2024. https://pubmed.ncbi.nlm.nih.gov/39535805/
- Quddos F, et al. Semaglutide and Tirzepatide reduce alcohol consumption in individuals with obesity. Scientific Reports. 2024. https://pmc.ncbi.nlm.nih.gov/articles/PMC10684505/
- Tirzepatide reduces alcohol drinking and relapse-like behaviours in rodents. eBioMedicine. 2025. https://pubmed.ncbi.nlm.nih.gov/41506148/
- Tirzepatide for Alcohol Use Disorder (Phase 2, University of Southern California, NIAAA). https://clinicaltrials.gov/study/NCT06994338
- Sison G, PharmD. Zepbound and alcohol: Is it safe to drink? SingleCare. Updated December 2025. https://www.singlecare.com/blog/zepbound-and-alcohol/
- Richards JR, et al. Significant Decrease in Alcohol Use Disorder Symptoms Secondary to Semaglutide Therapy for Weight Loss: A Case Series. The Journal of Clinical Psychiatry. 2024;85(1). https://www.psychiatrist.com/jcp/decreased-alcohol-use-disorder-symptoms-with-semaglutide-for-weight-loss-a-case-series
This article is for informational purposes and does not replace individualized medical advice. Talk to your provider before starting or stopping any medication.